Hersima (Trastuzumab Vials) 440mg/20ml

Hersima (Trastuzumab) 440mg/20ml vials are a targeted therapy for HER2-positive cancers. This monoclonal antibody helps slow cancer cell growth. Store between 2–8°C to maintain stability. Always follow healthcare provider guidance for use.

Strength

440mg/20ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Hetero Biopharma Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trastuzumab is primarily used to treat HER2-positive breast and gastric cancers. It may also be prescribed for early-stage or metastatic cases as part of combination therapy. Patients often ask, 'What is Trastuzumab used for?'—it targets HER2 protein overexpression to inhibit tumor progression. This medication is designed for systemic treatment under medical supervision.

Side Effects

Trastuzumab works by binding to HER2 receptors on cancer cells, slowing their growth. Many patients notice improved clinical outcomes over time. Common effects include fatigue, nausea, or headaches during treatment. Some may experience infusion-related reactions, which are typically monitored closely by healthcare professionals.

Precautions & Warnings

Hersima vials should be handled by trained medical staff to ensure proper administration. Always check the vial for particles or discoloration before use. Store refrigerated at 2–8°C and protect from light. Avoid freezing or shaking the vial to maintain potency. Discard any unused portion as per local guidelines.

Avoid Interactions

Trastuzumab may interact with other chemotherapy drugs or medications affecting the heart. Patients should inform their doctor about all prescriptions, over-the-counter drugs, or supplements. Alcohol use may exacerbate side effects like dizziness or nausea. Live vaccines are generally not recommended during treatment.

References

Frequently Asked Questions

Trastuzumab is used to treat HER2-positive breast and gastric cancers by targeting HER2 protein overexpression.

Hersima is administered via intravenous infusion under medical supervision, typically in a clinical setting.

Common side effects include fatigue, nausea, headaches, and infusion-related reactions.

Trastuzumab is a prescription medication and should only be obtained through licensed pharmacies or healthcare providers.

Store Hersima vials refrigerated at 2–8°C and protect from light; avoid freezing or shaking.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.